AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%

  • AstraZeneca Plc AZN and Daiichi Sankyo's DSKYF Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy.
  • Financial Times wrote 'oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer."
  • Detailed results from the DESTINY-Breast04 Phase 3 trial showed that Enhertu reduced the risk of disease progression or death versus chemotherapy by 49% in patients with HER2-low metastatic breast cancer with HR-positive disease.
  • Related: Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer.
  • A median progression-free survival (PFS) of 10.1 months was seen in patients treated with Enhertu compared to 5.4 months with chemotherapy.
  • Results also showed a 36% reduction in the risk of death with Enhertu compared to chemotherapy in patients with HR-positive disease with a median overall survival (OS) of 23.9 months with Enhertu versus 17.5 months with chemotherapy.
  • Price Action: AZN shares are down 0.97% at $65.06 during the premarket session on the last check Monday.
Posted In: BiotechLarge CapNewsHealth CareTop StoriesGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!